MiNK Therapeutics, Inc. has issued a current report on Form 8-K to clarify recent investor inquiries regarding potential combination trials involving its proprietary allogeneic iNKT cell therapy, agenT-797. The company is actively engaged in discussions with multiple parties about these trials, as well as potential strategic minority investments. This reflects a growing interest in MiNK's platform, particularly in addressing significant unmet medical needs such as critical illness. However, the company has not disclosed any binding agreements related to these discussions. The report emphasizes that while there is interest, no formal arrangements have been established yet. MiNK Therapeutics continues to navigate its strategic options while focusing on its operational execution and potential future growth in the biopharmaceutical sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.